Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

320 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of [18F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies.
Tezuka T, Takahata K, Seki M, Tabuchi H, Momota Y, Shiraiwa M, Suzuki N, Morimoto A, Nakahara T, Iwabuchi Y, Miura E, Yamamoto Y, Sano Y, Funaki K, Yamagata B, Ueda R, Yoshizaki T, Mashima K, Shibata M, Oyama M, Okada K, Kubota M, Okita H, Takao M, Jinzaki M, Nakahara J, Mimura M, Ito D. Tezuka T, et al. Among authors: tabuchi h. Brain Commun. 2021 Aug 24;3(4):fcab190. doi: 10.1093/braincomms/fcab190. eCollection 2021. Brain Commun. 2021. PMID: 34632382 Free PMC article.
Findings of 18 F-PI-2620 tau PET imaging in patients with Alzheimer's disease and healthy controls in relation to the plasma P-tau181 levels in a Japanese sample.
Bun S, Moriguchi S, Tezuka T, Sato Y, Takahata K, Seki M, Nakajima S, Yamamoto Y, Sano Y, Suzuki N, Morimoto A, Ueda R, Tabuchi H, Ito D, Mimura M. Bun S, et al. Among authors: tabuchi h. Neuropsychopharmacol Rep. 2022 Dec;42(4):437-448. doi: 10.1002/npr2.12281. Epub 2022 Jul 17. Neuropsychopharmacol Rep. 2022. PMID: 35843629 Free PMC article.
Impact of Amyloid and Tau PET on Changes in Diagnosis and Patient Management.
Shimohama S, Tezuka T, Takahata K, Bun S, Tabuchi H, Seki M, Momota Y, Suzuki N, Morimoto A, Iwabuchi Y, Kubota M, Yamamoto Y, Sano Y, Shikimoto R, Funaki K, Mimura Y, Nishimoto Y, Ueda R, Jinzaki M, Nakahara J, Mimura M, Ito D. Shimohama S, et al. Among authors: tabuchi h. Neurology. 2023 Jan 17;100(3):e264-e274. doi: 10.1212/WNL.0000000000201389. Epub 2022 Sep 29. Neurology. 2023. PMID: 36175151
Performance of plasma Aβ42/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status.
Bun S, Ito D, Tezuka T, Kubota M, Ueda R, Takahata K, Moriguchi S, Kurose S, Momota Y, Suzuki N, Morimoto A, Hoshino Y, Seki M, Mimura Y, Shikimoto R, Yamamoto Y, Hoshino T, Sato Y, Tabuchi H, Mimura M. Bun S, et al. Among authors: tabuchi h. Alzheimers Res Ther. 2023 Sep 4;15(1):149. doi: 10.1186/s13195-023-01296-5. Alzheimers Res Ther. 2023. PMID: 37667408 Free PMC article.
Impact of a combination of quantitative indices representing uptake intensity, shape, and asymmetry in DAT SPECT using machine learning: comparison of different volume of interest settings.
Iwabuchi Y, Nakahara T, Kameyama M, Yamada Y, Hashimoto M, Matsusaka Y, Osada T, Ito D, Tabuchi H, Jinzaki M. Iwabuchi Y, et al. Among authors: tabuchi h. EJNMMI Res. 2019 Jan 28;9(1):7. doi: 10.1186/s13550-019-0477-x. EJNMMI Res. 2019. PMID: 30689072 Free PMC article.
Disclosure of Amyloid Status for Risk of Alzheimer Disease to Cognitively Normal Research Participants With Subjective Cognitive Decline: A Longitudinal Study.
Wake T, Tabuchi H, Funaki K, Ito D, Yamagata B, Yoshizaki T, Nakahara T, Jinzaki M, Yoshimasu H, Tanahashi I, Shimazaki H, Mimura M. Wake T, et al. Among authors: tabuchi h. Am J Alzheimers Dis Other Demen. 2020 Jan-Dec;35:1533317520904551. doi: 10.1177/1533317520904551. Am J Alzheimers Dis Other Demen. 2020. PMID: 32052640 Free PMC article.
320 results